

AMENDMENT AND RESPONSE UNDER 37 CFR § 1.111

Serial Number: 10/028,547

Filing Date: December 19, 2001

Title: METHODS OF TREATING FIBROMYALGIA, CHRONIC FATIGUE SYNDROME AND PAIN

Page 2

Dkt: 1666.003US1

6. (Once amended) The method according to claim 1, wherein the compound is adjunctively administered with neurontin, pregabalin, pramipexole, 1-DOPA, amphetamine, tizanidine, clonidine, tramadol, morphine, codeine, carbamazepine, sibutramine, [amphetamine,] valium, [or] trazodone, or a combination thereof.

26. (New) The method of claim 1 wherein the compound is administered alone.

27. (New) The method of claim 1 wherein milnacipran is not administered adjunctively with a muscle relaxant.

28. (New) A method of treating fibromyalgia syndrome (FMS), physiological symptoms associated therewith, or a combination thereof in an animal subject, the method consisting essentially of administering to an animal subject suffering from FMS, an effective amount of milnacipran, or a pharmaceutically acceptable salt thereof.

29. (New) A method of treating fibromyalgia syndrome (FMS), physiological symptoms associated therewith, or a combination thereof in an animal subject, the method consisting essentially of administering to an animal subject suffering from FMS, an effective amount of milnacipran or a pharmaceutically acceptable salt thereof, adjunctively with an antidepressant, anorectic, analgesic, antiepileptic drug, muscle relaxant, sedative, hypnotic, or a combination thereof.

30. (New) The method of claim 29 wherein the milnacipran or pharmaceutically acceptable salt thereof is administered adjunctively with an anorectic, analgesic, antiepileptic drug, sedative, hypnotic, or a combination thereof.

REMARKS

Reconsideration and withdrawal of the rejections of the claims in view of the amendments and remarks presented herein is respectfully requested.